IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo

Nature

Volumn 517, Issue 7536, 2015, Pages 626-630

  Venkatanarayan, Avinashnarayan ^a,b   Raulji, Payal ^a   Norton, William ^a   Chakravarti, Deepavali ^a,b   Coarfa, Cristian ^c   Su, Xiaohua ^a   Sandur, Santosh K ^a,d   Ramirez, Marc S ^a   Lee, Jaehuk ^a   Kingsley, Charles V ^a   Sananikone, Eliot F ^a,b   Rajapakshe, Kimal ^c   Naff, Katherine ^a   Parker Thornburg, Jan ^a   Bankson, James A ^a   Tsai, Kenneth Y ^a,e   Gunaratne, Preethi H ^f   Flores, Elsa R ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BHABHA ATOMIC RESEARCH CENTRE   (India)

^e University of Texas Health Science Center at Houston   (United States)

^f University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; CALCITONIN RECEPTOR; GENOMIC DNA; INSULIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PRAMLINTIDE; TRANSACTIVATOR PROTEIN; TRP63 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENE DELETION; GENE OVEREXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; METABOLIC REPROGRAMMING; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RNA SEQUENCE; THYMUS LYMPHOMA; TRANSACTIVATION; UPREGULATION; ANIMAL; CELL TRANSFORMATION; DEFICIENCY; FEMALE; GENETICS; LYMPHOMA; MALE; METABOLISM; PATHOLOGY; SECRETION (PROCESS); THYMUS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; ISLET AMYLOID POLYPEPTIDE; LYMPHOMA; MALE; MICE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; RECEPTOR ACTIVITY-MODIFYING PROTEIN 3; RECEPTORS, CALCITONIN; THYMUS GLAND; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84925538910     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13910     Document Type: Article

References (47)

1. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
2. Wang, Y. et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J. Clin. Invest. 121, 893-904 (2011).
3. Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for thep53family.CancerCell 7,363-373 (2005).
4. Su, X. et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467, 986-990 (2010).
5. Su, X., Chakravarti, D.& Flores, E. R. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nature Rev. Cancer 13, 136-143 (2013).
6. Tomasini, R. et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677-2691 (2008).
7. Yang, A. et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316 (1998).
8. Su, X. et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 16, 511-525 (2012).
9. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002)
10. Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy programcontributing to key p53 responses. Genes Dev. 27, 1016-1031 (2013).
11. Di Como, C. J., Gaiddon, C. & Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449 (1999).
12. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives, C. A subset of tumor-derived mutant forms ofp53 down-regulate p63and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1887 (2001).
13. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004).
14. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
15. Chakravarti, D. et al. Induced multipotency in adult keratinocytes through downregulation of DNp63 or DGCR8. Proc. Natl Acad. Sci. USA 111, E572-E581 (2014).
16. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
17. Attardi, L. D., de Vries, A.&Jacks, T. Activation of thep53-dependentG1checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23, 973-980 (2004).
18. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006).
19. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012).
20. Suzuki, S. et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl Acad. Sci. USA 107, 7461-7466 (2010).
21. Castle, A. L., Kuo, C. H., Han, D. H. & Ivy, J. L. Amylin-mediated inhibition of insulinstimulated glucose transport in skeletal muscle. Am. J. Physiol. 275, E531-E536 (1998).
22. Edelman, S., Maier, H. & Wilhelm, K. Pramlintide in the treatment of diabetes mellitus. BioDrugs 22, 375-386 (2008).
23. Mattson, M. P. & Goodman, Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676, 219-224 (1995).
24. Schubert, D. et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl Acad. Sci. USA 92, 1989-1993 (1995).
25. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nature Rev. Cancer 11, 85-95 (2011).
26. Pillay, K. & Govender, P. Amylin uncovered: a review on the polypeptide responsible for type II diabetes. BioMed Res. Int. 2013, 826706 (2013).
27. Christopoulos, G. et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56, 235-242 (1999).
28. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanismfor enhanced IL-1b in type 2 diabetes. Nature Immunol. 11, 897-904 (2010).
29. Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
30. Vin, H. et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. eLife 2, e00969 (2013).
31. Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476-484 (2003).
32. Lewandoski, M., Wassarman, K. M.& Martin, G. R. Zp3-cre, a transgenicmouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr. Biol. 7, 148-151 (1997).
33. Jackson, J. G. et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21, 793-806 (2012).
34. Su, X. et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 5, 64-75 (2009).
35. Lin, Y. L. et al. p63 and p73 transcriptionally regulate genes involved inDNA repair. PLoS Genet. 5, e1000680 (2009).
36. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnol. 28, 511-515 (2010).
37. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large genelists usingDAVIDbioinformatics resources.Nature Protocols 4,44-57 (2009).
38. Ardenkjaer-Larsen, J. H. et al. Increase in signal-to-noise ratio of.10,000 times in liquid-state NMR. Proc. Natl Acad. Sci. USA 100, 10158-10163 (2003).
39. Sandulache, V. C. et al. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol. Cancer Ther. 11, 1373-1380 (2012).
40. Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542-546 (2013).
41. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
42. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
43. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
44. The Cancer Genome Atlas Network. Comprehensivemolecular portraits of human breast tumours. Nature 490, 61-70 (2012).
45. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
46. The Cancer Genome Atlas Network.Comprehensivemolecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
47. Cerami, E. et al. The cBio Cancer Genomics Portal: an open platformfor exploring multidimensional cancer genomics data. Cancer Discovery 2, 401-404 (2012).